Home
Remegen

Remegen Market Share Analysis for August 2026

Industry: N/A

Domainremegen.com

Year Founded2008

Employees1001 - 5000

Annual Revenue--

Remegen

Remegen (including company regionals)

remegen.com

See more website traffic and engagement information

Total visits to Remegen's top domains

Understand Remegen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

remegen.com2.4K

See more with Sales Intelligence

Avg. visit duration in Remegen's top domains

Analyze Remegen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

remegen.com00:03:18

See more with Sales Intelligence

Avg. pageviews on Remegen's top domains

See how Remegen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

remegen.com3.40

See more with Sales Intelligence

Remegen top competitors by domain

Top similar sites in August 2026, ranked by their affinity

biopharmadive.comCompany NameBioPharma DiveEmployees51 - 200HQUnited States, Washington, WashingtonAnnual revenue$10M - $15MTotal visits191.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Remegen

These are the website technologies, by industry, used by Remegen top domains

Mobile (3)

Meta Viewport

Social (3)

Facebook Social Plugins

Advertising (2)

PubMatic

Conversion & Analytics (2)

Google Analytics

More Technologies

5

See all

News & Signals from Remegen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAbbVie Inc. partnered with RemeGen, Ltd. on Aug 21st '26.* ABBV-1480 (RC148): AbbVie, in partnership with RemeGen, will present Phase 1b data evaluating the investigational PD-1/VEGF bispecific antibody, ABBV-1480, in combination with platinum-based chemotherapy as a potential first-line treatment for advanced NSCLC.

NewsRemeGen, Ltd. had revenue of $867M on Jun 30th '26.RemeGen Co., Ltd. projects operating revenue of approximately RMB5,850m for the six months ended June 30, 2026, marking a 433% year-on-year increase from RMB1,097.9m.

NewsRemeGen, Ltd. is developing novel PD-1/VEGF bispecific on Jan 12th '26.* Jan 12: AbbVie and RemeGen Biosciences announce licensing agreement to develop a novel PD-1/VEGF bispecific in potential $5.6B deal.